Enhancing the Efficacy of Immunotherapeutic Drugs for Prostate Cancer – Dr Douglas McNeel, MD PhD, University of Wisconsin

Jun 14, 2019 | biology, health and medicine

Prostate cancer is a leading cause of male cancer deaths worldwide, with one man in every seven likely to contract the disease during his lifetime. As late-stage prostate cancer remains a fatal disease resistant to conventional treatment, the need for effective new therapies is dire. Dr Douglas McNeel, a Professor of Medicine in the Haemato-Oncology Division of the University of Wisconsin’s Carbone Cancer Centre, has been working to meet this need.

Original article reference:


More SciPods you may like

Did you enjoy this SciPod? Do you want your own?